Shares of Teva Pharmaceutical Industries surged 8.9% to $40.13 in extended trading on September 9, after Leerink Partners launched coverage with an Outperform rating and a $45 price target, implying roughly 12% additional upside from current levels. The move — concentrated in after-hours buying with no earnings catalyst — signals that at least one corner of Wall Street believes Teva's turnaround has legs. Leerink Bets Teva's Generic-Drug Past Is Behind It — But Is a $45 Target Too Generous for a Company With Shrinking Revenue?
Shares of Teva Pharmaceutical jumped 8.9% to $40.13 in after-hours trading September 9 after Leerink Partners initiated coverage with an Outperform rating and a $45 price target — a vote of confidence that the world's largest generic-drug maker can reinvent itself as a branded-medicine company. The sharp move came on no earnings news, underscoring how hungry investors are for a fresh bull case on a stock that had drifted below $37 for six straight sessions.
• Teva's Branded Drugs Are Growing Fast, but the Old Business Is Fading. Teva's three key branded medicines collectively grew 43% year-over-year in Q2 2026 to over $1 billion in quarterly revenue. That's impressive — but total company revenue fell 1% to $4.14 billion in Q2, dragged down by declining generic-drug sales, especially as a key generic lost exclusivity. Leerink's growth thesis hinges on branded products outpacing generic erosion — a race that isn't won yet.
• A $10 Billion Pipeline Sounds Big, but the Biggest Bets Are Unproven. Teva says its innovative pipeline holds $10 billion in long-run revenue potential.
The FDA accepted Teva's application for a once-monthly schizophrenia injection, with a planned launch in Q4 2026.
Truist estimates that drug alone could unlock a $3 billion sales opportunity. Meanwhile, Teva paid $700 million to acquire Emalex Biosciences for a Tourette syndrome therapy , adding pipeline depth but near-term costs.
• Profit Margins Are Improving, but a Revenue Dip Looms. Non-GAAP gross profit margin climbed to 55.4% in Q2 2026, up from 54.6% a year earlier , reflecting the shift toward higher-margin branded drugs. Management says it's on track for a 30% operating margin by 2027. Still, Teva's own 2026 revenue guidance of $16.4–$16.8 billion signals a decline from 2025's $17.3 billion , meaning the margin story must carry shareholder returns until pipeline products arrive.
• The $45 Target Asks Investors to Pay for the Future Today. At $40.13, the stock has already absorbed much of the upgrade. The remaining ~12% to Leerink's target demands belief that branded drug momentum and late-stage pipeline wins will offset a generics business that is structurally shrinking. A recent Fitch upgrade to investment-grade credit is a positive signal for financial stability , but the stock's near-term trajectory now depends on FDA decisions and prescription trends, not analyst initiations.